OR WAIT null SECS
Fingerpaint, biopharma’s global commercialization partner for analytics-enabled integrated solutions, announced the appointment of Bill McEllen as global president effective immediately.
A Fingerpaint partner, McEllen will continue to build on the exponential year-over-year growth the company has experienced, set in motion by Fingerpaint founder Ed Mitzen, who will serve as Fingerpaint’s chairman and CEO. This move will allow Mitzen to continue focusing on growing the company’s capabilities through acquisitions.
“Bill’s experience and extensive understanding of the global challenges faced by the evolving biopharma landscape make him a natural fit to lead the company while staying true to the foundation Fingerpaint was built on,” said Mitzen. “Our people and our clients will continue to benefit from his forward-thinking approach.”
“I am humbled and excited to be stepping into this new role at such a pivotal time in the biopharma industry—and for our company,” said McEllen, who will report to Mitzen. “Our innovative commercialization capabilities help create solutions that transform beliefs, behavior, and performance and, ultimately, mean better outcomes for patients.”